MYC and acute myeloid leukemia: Preclinical investigations reveal that FHD-286 promotes chromatin compaction, inhibits oncogenic regulators such as c-Myc and PU.1, and diminishes leukemia-initiating potential in acute myeloid leukemia (AML) models [254].